Verdence Capital Advisors LLC Makes New Investment in IQVIA Holdings Inc. $IQV

Key Points

• Verdence Capital Advisors LLC has purchased 22,922 shares of IQVIA Holdings Inc., valued at approximately $3.61 million, marking a new investment in the company in the second quarter.
• Analysts have a consensus rating of "Moderate Buy" for IQVIA, with an average price target of $236.45, reflecting strong optimism towards the company's future performance.
• IQVIA reported a quarterly earnings per share of $2.81, surpassing expectations and showing a 5.3% increase in revenue year-over-year.

Verdence Capital Advisors LLC acquired a new position in IQVIA Holdings Inc. (NYSE:IQV - Free Report) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 22,922 shares of the medical research company's stock, valued at approximately $3,612,000.

Other institutional investors have also added to or reduced their stakes in the company. Clal Insurance Enterprises Holdings Ltd lifted its stake in IQVIA by 436.7% in the first quarter. Clal Insurance Enterprises Holdings Ltd now owns 161 shares of the medical research company's stock worth $28,000 after purchasing an additional 131 shares during the last quarter. Golden State Wealth Management LLC raised its stake in shares of IQVIA by 295.5% during the first quarter. Golden State Wealth Management LLC now owns 174 shares of the medical research company's stock valued at $31,000 after acquiring an additional 130 shares in the last quarter. AllSquare Wealth Management LLC bought a new stake in shares of IQVIA during the first quarter valued at approximately $33,000. Trust Co. of Toledo NA OH bought a new stake in shares of IQVIA during the second quarter valued at approximately $39,000. Finally, Larson Financial Group LLC raised its stake in shares of IQVIA by 109.9% during the first quarter. Larson Financial Group LLC now owns 275 shares of the medical research company's stock valued at $48,000 after acquiring an additional 144 shares in the last quarter. Institutional investors own 89.62% of the company's stock.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on the stock. Cowen reaffirmed a "buy" rating on shares of IQVIA in a research note on Wednesday, July 23rd. Redburn Partners set a $214.00 price target on shares of IQVIA in a research note on Wednesday, September 3rd. Barclays lifted their price target on shares of IQVIA from $185.00 to $200.00 and gave the company an "equal weight" rating in a research note on Thursday, October 2nd. Evercore ISI lifted their price target on shares of IQVIA from $220.00 to $240.00 and gave the company an "outperform" rating in a research note on Wednesday. Finally, Weiss Ratings reissued a "hold (c)" rating on shares of IQVIA in a report on Wednesday, October 8th. One analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and five have given a Hold rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $236.45.

IQVIA Stock Performance

Shares of IQV stock opened at $198.35 on Monday. The firm has a market cap of $33.72 billion, a price-to-earnings ratio of 28.70, a PEG ratio of 2.18 and a beta of 1.32. The company's 50 day moving average is $189.02 and its 200 day moving average is $168.11. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.45. IQVIA Holdings Inc. has a 52-week low of $134.65 and a 52-week high of $237.34.

IQVIA (NYSE:IQV - Get Free Report) last released its quarterly earnings results on Tuesday, July 22nd. The medical research company reported $2.81 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.77 by $0.04. IQVIA had a net margin of 7.88% and a return on equity of 30.05%. The business had revenue of $4.02 billion for the quarter, compared to analyst estimates of $3.96 billion. During the same period in the previous year, the company earned $2.64 earnings per share. The business's revenue for the quarter was up 5.3% on a year-over-year basis. IQVIA has set its FY 2025 guidance at 11.750-12.050 EPS. On average, sell-side analysts anticipate that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

Insider Buying and Selling at IQVIA

In other IQVIA news, insider Keriann Cherofsky sold 549 shares of IQVIA stock in a transaction on Wednesday, July 23rd. The shares were sold at an average price of $191.53, for a total value of $105,149.97. Following the transaction, the insider directly owned 2,910 shares of the company's stock, valued at approximately $557,352.30. The trade was a 15.87% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Eric Sherbet sold 5,800 shares of IQVIA stock in a transaction on Wednesday, July 23rd. The stock was sold at an average price of $190.05, for a total transaction of $1,102,290.00. Following the completion of the transaction, the insider directly owned 27,178 shares in the company, valued at $5,165,178.90. This represents a 17.59% decrease in their ownership of the stock. The disclosure for this sale can be found here. 1.60% of the stock is currently owned by insiders.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IQVIA Holdings Inc. (NYSE:IQV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.